According to a recent LinkedIn post from AG1, the company is highlighting rapid growth in GLP-1 medication use in the U.S., noting that nearly 15 million Americans, or roughly one in eight adults, are now users. The post frames this as a major shift in modern health where nutrition science is still adapting.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that AG1 is supporting new independent studies at Penn State University examining links between GLP-1 medications, eating behavior, and nutritional status. The research, led by Dr. Travis Masterson, will explore dietary intake, perceptions of “food noise,” and long-term nutritional health.
For investors, the post suggests AG1 is positioning itself at the intersection of GLP-1 therapy and nutrition, a rapidly evolving segment with significant commercial potential. Aligning with academic research could enhance the brand’s credibility, inform future product positioning, and support differentiation as more supplement and wellness companies target GLP-1 users.
The emphasis on rigorous, independent scientific research may also be intended to mitigate concerns about product efficacy in a market where evidence-based positioning is increasingly important. If the studies yield publishable findings, AG1 could gain valuable data assets, thought-leadership opportunities, and potential leverage in partnerships with healthcare or digital health players.